Literature DB >> 29144165

Gene therapy: evidence, value and affordability in the US health care system.

Grace Hampson1, Adrian Towse1, Steven D Pearson2, William B Dreitlein2, Chris Henshall1,3.   

Abstract

AIMS: To explore the challenges presented by gene therapies, discuss potential solutions, and present policy recommendations.
METHODS: A review of the literature and series of expert interviews were conducted and discussed at a Policy Forum convened by The Institute for Clinical and Economic Review (ICER). The Policy Forum was attended by independent experts and senior representatives from 20 payer organizations and life sciences companies.
RESULTS: Three categories of challenges are identified: evidence generation, assessing value and affordability. Possible solutions and policy recommendations are presented for each of the three main categories of challenges.
CONCLUSIONS: Gene therapies present exciting opportunities, but also pose major challenges. Dialogue between manufacturers and payers around the issues and possible solutions is crucial.

Keywords:  affordability; evidence; gene therapy; health technology assessment; recommendations; safety; value assessment; value framework

Mesh:

Year:  2017        PMID: 29144165     DOI: 10.2217/cer-2017-0068

Source DB:  PubMed          Journal:  J Comp Eff Res        ISSN: 2042-6305            Impact factor:   1.744


  20 in total

1.  Recalibrating Health Technology Assessment Methods for Cell and Gene Therapies.

Authors:  Aris Angelis; Huseyin Naci; Allan Hackshaw
Journal:  Pharmacoeconomics       Date:  2020-12       Impact factor: 4.981

Review 2.  Addressing the Value of Gene Therapy and Enhancing Patient Access to Transformative Treatments.

Authors:  Rachel Salzman; Francesca Cook; Timothy Hunt; Harry L Malech; Philip Reilly; Betsy Foss-Campbell; David Barrett
Journal:  Mol Ther       Date:  2018-10-30       Impact factor: 11.454

Review 3.  Pricing and Market Access Challenges in the Era of One-Time Administration Cell and Gene Therapies.

Authors:  Marco T Sabatini; Tia Xia; Mark Chalmers
Journal:  Pharmaceut Med       Date:  2022-08-22

4.  Assessing potential cures: are there distinctive elements of value beyond health gain?

Authors:  Saskia Hendriks; Steven D Pearson
Journal:  J Comp Eff Res       Date:  2021-03-05       Impact factor: 1.744

Review 5.  The Equitable Implementation of Cystic Fibrosis Personalized Medicines in Canada.

Authors:  Genevieve Shemie; Minh Thu Nguyen; John Wallenburg; Felix Ratjen; Bartha Maria Knoppers
Journal:  J Pers Med       Date:  2021-05-07

Review 6.  Autism spectrum disorder: prospects for treatment using gene therapy.

Authors:  Matthew Benger; Maria Kinali; Nicholas D Mazarakis
Journal:  Mol Autism       Date:  2018-06-20       Impact factor: 7.509

Review 7.  Development and Clinical Translation of Approved Gene Therapy Products for Genetic Disorders.

Authors:  Alireza Shahryari; Marie Saghaeian Jazi; Saeed Mohammadi; Hadi Razavi Nikoo; Zahra Nazari; Elaheh Sadat Hosseini; Ingo Burtscher; Seyed Javad Mowla; Heiko Lickert
Journal:  Front Genet       Date:  2019-09-25       Impact factor: 4.599

Review 8.  Voretigene Neparvovec and Gene Therapy for Leber's Congenital Amaurosis: Review of Evidence to Date.

Authors:  Srikanta Kumar Padhy; Brijesh Takkar; Raja Narayanan; Pradeep Venkatesh; Subhadra Jalali
Journal:  Appl Clin Genet       Date:  2020-11-25

9.  Evidence generation and reproducibility in cell and gene therapy research: A call to action.

Authors:  Mohamed Abou-El-Enein; Aris Angelis; Frederick R Appelbaum; Nancy C Andrews; Susan E Bates; Arlene S Bierman; Malcolm K Brenner; Marina Cavazzana; Michael A Caligiuri; Hans Clevers; Emer Cooke; George Q Daley; Victor J Dzau; Lee M Ellis; Harvey V Fineberg; Lawrence S B Goldstein; Stephen Gottschalk; Margaret A Hamburg; Donald E Ingber; Donald B Kohn; Adrian R Krainer; Marcela V Maus; Peter Marks; Christine L Mummery; Roderic I Pettigrew; Joni L Rutter; Sarah A Teichmann; Andre Terzic; Fyodor D Urnov; David A Williams; Jedd D Wolchok; Mark Lawler; Cameron J Turtle; Gerhard Bauer; John P A Ioannidis
Journal:  Mol Ther Methods Clin Dev       Date:  2021-07-21       Impact factor: 6.698

10.  Health economic evaluation of gene replacement therapies: methodological issues and recommendations.

Authors:  Samuel Aballéa; Katia Thokagevistk; Rimma Velikanova; Steven Simoens; Lieven Annemans; Fernando Antonanzas; Pascal Auquier; Clément François; Frank-Ulrich Fricke; Daniel Malone; Aurélie Millier; Ulf Persson; Stavros Petrou; Omar Dabbous; Maarten Postma; Mondher Toumi
Journal:  J Mark Access Health Policy       Date:  2020-10-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.